ERYTECH Pharma S.A.

Corporate Details

ISIN(s):

FR0010417360 (+2 more)

LEI:

969500U8ZZCODU8A9374

Country:

France

Address:

60 AVENUE ROCKEFELLER, 69008 LYON

Website:

https://erytech.com

Sector:

Professional, scientific and technical activities

Industry:

Research and experimental development on natural sciences and engineering

Description

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival. The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell’s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of first-line triple-negative breast cancer.